Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
49%
Hematopoietic Cell Transplantation
41%
Transplantation
35%
T Cells
32%
Umbilical Cord Blood
32%
Unrelated Donor
29%
Bone Marrow Transplantation
28%
Hematopoietic Stem Cell Transplantation
25%
Umbilical Cord Blood Transplantation
23%
Natural Killer Cells
23%
Bone Marrow
23%
Hematopoietic Stem Cells
21%
Photosystem II
18%
Engraftment
18%
Overall Survival
17%
Confidence Interval
17%
Fanconi Anemia
16%
Treg
15%
Epidermolysis Bullosa
14%
Regulatory T Cells
13%
Marrow Transplantation
13%
Adrenoleukodystrophy
12%
Allogeneic Bone Marrow Transplantation
12%
Acute Myeloid Leukemia
12%
Hurler Syndrome
12%
Embryonic Stem Cells
11%
Pediatric
11%
Transplant Outcomes
11%
Acute Leukemia
11%
Chemotherapy
10%
Marrow
10%
Cyclophosphamide
10%
B Cells
9%
Reduced-intensity Conditioning
9%
Clinical Outcomes
9%
Allogeneic
9%
Tumor
8%
Pediatric Patients
8%
Donor T Cell
8%
Hematopoietic Cell Transplant
8%
Cell Therapy
8%
Stem Cells
8%
Leukemia
8%
Diffuse Large B-cell Lymphoma (DLBCL)
8%
Lung
8%
Myeloablative Conditioning
8%
HLA Matching
8%
Pretransplant
7%
DUX4
7%
Acute Lymphoblastic Leukemia
7%
Hazard Ratio
7%
Induced Pluripotent Stem Cells (iPSCs)
7%
Mouse Model
7%
CD8+ T Cells
7%
Cord Blood Transplantation
7%
Interleukin-2
7%
High Risk
7%
Lymphoma
7%
Hematological Malignancies
7%
Conditioning Regimen
7%
Hematopoietic Cells
7%
Gene Therapy
7%
Myelodysplastic Syndrome
6%
Mesenchymal Stem Cells
6%
Transcription Factor
6%
HLA-matched Donor
6%
Lethality
6%
Immune Response
6%
CD4+
6%
Risk Factors
6%
Gene Expression
6%
Allogeneic Transplantation
6%
Hematopoietic Stem Cell Transplant
6%
Stem Cell-derived
6%
Dendritic Cells
6%
Cord Blood Unit
6%
Total Body Irradiation
6%
Granulocyte Colony-stimulating Factor (G-CSF)
5%
Peripheral Blood
5%
Facioscapulohumeral muscular Dystrophy
5%
Fludarabine
5%
Unrelated Donor Transplantation
5%
T Cell Activation
5%
Osteopetrosis
5%
T Cell Depletion
5%
Sickle Cell Disease
5%
Lymphoma Patients
5%
Busulfan
5%
Myeloablative
5%
Older Adults
5%
Cell Dose
5%
Clinical Trials
5%
Lymphocytes
5%
Graft Failure
5%
Regulatory T (Treg) Cells
5%
Prognostic Factors
5%
Disease-free Survival
5%
Bone Marrow Cells
5%
Stem Cell Source
5%
Immunology and Microbiology
Hematopoietic Cell
69%
Graft-Versus-Host Disease
67%
T Cell
55%
Cell Transplantation
44%
Umbilical Cord Blood
44%
Acute Graft Versus Host Disease
31%
Regulatory T Cell
28%
Natural Killer Cell
25%
Bone Marrow Transplantation
24%
Cord Blood Stem Cell Transplantation
23%
Conditioning
22%
Engraftment
21%
Chronic Graft Versus Host Disease
20%
Hematopoietic Stem Cell Transplantation
19%
B Cell
17%
Overall Survival
15%
Myeloid
14%
Stem Cell
14%
Allogeneic Hematopoietic Stem Cell Transplantation
11%
Lymphocyte
11%
T-Helper Cell
10%
Cyclophosphamide
10%
Cytokine
10%
Cytotoxic T-Cell
9%
Allograft
9%
Lineages
9%
CD4
8%
Immune Response
7%
Neutrophil
7%
Mesenchymal Stem Cell
7%
CD34
7%
Dendritic Cell
7%
Interleukin 2
6%
Allele
6%
Allogeneic Bone Marrow Transplantation
6%
Human Leukocyte Antigen
6%
Cell Function
5%
Ciclosporin
5%
Medicine and Dentistry
Hematopoietic Cell
65%
Cell Transplantation
45%
Graft Versus Host Reaction
33%
Diseases
30%
Cord Blood
27%
Hematopoietic Stem Cell Transplantation
23%
T Cell
21%
Bone Marrow Transplantation
21%
Overall Survival
18%
Hurler Syndrome
17%
Acute Graft Versus Host Disease
16%
Stem Cell
14%
Pediatrics
14%
Cord Blood Stem Cell Transplantation
13%
Chronic Graft Versus Host Disease
13%
Engraftment
12%
Fanconi Anemia
12%
Neoplasm
12%
Leukemia
10%
Acute Lymphoblastic Leukemia
10%
In Vitro
10%
B Cell
9%
Epidermolysis Bullosa Dystrophica
9%
Adrenoleukodystrophy
8%
Allogeneic Hematopoietic Stem Cell Transplantation
8%
Allograft
8%
Cell Therapy
8%
Acute Leukemia
8%
Conditioning
8%
Mucopolysaccharidosis
7%
Acute Myeloid Leukemia
7%
Progenitor Cell
7%
Lung
7%
Diffuse Large B-Cell Lymphoma
7%
Mesenchymal Stem Cell
7%
Natural Killer Cell
6%
Regulatory T Cell
6%
Pediatrics Patient
6%
Myelodysplastic Syndrome
6%
Prognostic Factor
6%
Lymphocyte
6%
Clinical Trial
6%
Biological Marker
6%
Embryonic Stem Cell
6%
Disease
6%
Gene Therapy
5%
Hematologic Malignancy
5%
Hazard Ratio
5%
Cyclophosphamide
5%